Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Mitsui Acquires Stake In India's Arch Pharma For Direct Presence In The "Global Factory"

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD, India - After Japanese drug giants Daiichi Sankyo, Eisai, Astellas and Takeda, it is the turn of Mitsui - one of the largest and most diverse Japanese industry conglomerates - to evince a direct interest in the Indian pharmaceutical industry

You may also be interested in...



India’s Deal Street Heats Up: Claris, Otsuka, Mitsui In JV To Tap Emerging Markets

The new company will leverage manufacturing and product development competencies to reach out to emerging markets.

Hikma Takes Significant Minority Stake In India's Unimark To Boost Presence Across Global Markets

MUMBAI - Hikma Pharmaceuticals PLC announced it acquired a minority strategic stake in Unimark Remedies Ltd. - a fast-growing Indian intermediates and API manufacturing firm - for $33 million, which could help the Jordanian generics firm expand beyond its Middle East and North Africa (MENA) focus and ramp up capability for the U.S. market

Hikma Takes Significant Minority Stake In India's Unimark To Boost Presence Across Global Markets

MUMBAI - Hikma Pharmaceuticals PLC announced it acquired a minority strategic stake in Unimark Remedies Ltd. - a fast-growing Indian intermediates and API manufacturing firm - for $33 million, which could help the Jordanian generics firm expand beyond its Middle East and North Africa (MENA) focus and ramp up capability for the U.S. market

Related Content

UsernamePublicRestriction

Register

SC075988

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel